Kanabidiol
Kanabidiola edo CBD kalamuan dauden 113 kannabinoideetako bat da, eta kalamu barietateetan landarearen osagai nagusia da[1].
Kanabidiol | |
---|---|
Formula kimikoa | C21H30O2 |
SMILES kanonikoa | 2D eredua |
SMILES isomerikoa | CCCCCC1=CC(=C(C(=C1)O)[C@@H]2C=C(CC[C@H]2C(=C)C)C)O |
MolView | 3D eredua |
Konposizioa | karbono |
Mota | [[2-[(6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol|2-[(6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol]] (en) |
Estereoisomeroa | [[1,3-Benzenediol, 2-[3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-, (1R-trans)-|1,3-Benzenediol, 2-[3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-, (1R-trans)-]] (en) |
Ezaugarriak | |
Fusio-puntua | 66 °C |
Masa molekularra | 314,22458 Da |
Erabilera | |
Elkarrekintza | G protein-coupled receptor 18 (en) , G protein-coupled receptor 55 (en) , Transient receptor potential cation channel subfamily M member 8 (en) eta Transient receptor potential cation channel subfamily V member 2 (en) |
Identifikatzaileak | |
InChlKey | QHMBSVQNZZTUGM-ZWKOTPCHSA-N |
CAS zenbakia | 13956-29-1 |
ChemSpider | 559095 |
PubChem | 644019 |
Gmelin | 69478 |
ChEMBL | CHEMBL190461 |
EC zenbakia | 689-176-3 |
ECHA | 100.215.986 |
CosIng | 93486 |
MeSH | D002185 |
RxNorm | 2045371 |
KNApSAcK | C00002641 |
UNII | 19GBJ60SN5 |
PDB Ligand | P0T |
Tetrahidrokanabinola (THC) ez bezala, kalamua ez da psikoaktiboa eta aplikazio medikoetarako irismen zabalagoa duela uste da —epilepsia[2] eta entzefalopatia epileptikoak barne, hala nola Westen sindromea, esklerosi anizkoitza[3], antsietate-desordenak, eskizofrenia[4] eta goragalea—. Ondorio lasaigarria eragiten du kasu gehienetan, eta minarekin lotutako nerbio-seinaleen transmisioa inhibitzen du. Ikusi da CBDk in vitro giza bularreko minbiziaren zelulen hazkundea murrizten duela eta haien inbasibitatea murrizten duela[5].
Berez, CBD ez da intoxikatzailea, baina THCren eragin euforikoa moderatzen duela dirudi, kalamuaren isomeroa dena eta ezaugarri lasaigarri bat gehitzen diona[6]. Hala ere, zenbait ikerketak iradokitzen dute CBDak alerta egoera areagotu dezakeela[7]. Jakina da organismotik THCa ezabatzeko abiadura murriztu dezakeela, beharbada gibelean THCaren metabolismoa oztopatzean. Ez dirudi datuen oinarrizko multzoak hartzaileei eragiten dienik, ez CB1ari, ez CB2ri[8].
Erreferentzia
aldatu- ↑ Aizpurua-Olaizola, Oier; Soydaner, Umut; Öztürk, Ekin; Schibano, Daniele; Simsir, Yilmaz; Navarro, Patricia; Etxebarria, Nestor; Usobiaga, Aresatz. (2016-02-26). «Evolution of the Cannabinoid and Terpene Content during the Growth of Cannabis sativa Plants from Different Chemotypes» Journal of Natural Products 79 (2): 324–331. doi: . ISSN 0163-3864. (Noiz kontsultatua: 2020-09-06).
- ↑ Jones, Nicholas A.; Glyn, Sarah E.; Akiyama, Satoshi; Hill, Thomas D.M.; Hill, Andrew J.; Weston, Samantha E.; Burnett, Matthew D.A.; Yamasaki, Yuki et al.. (2012-06). «Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures» Seizure 21 (5): 344–352. doi: . ISSN 1059-1311. (Noiz kontsultatua: 2020-09-06).
- ↑ (Ingelesez) Kozela, Ewa; Lev, Nirit; Kaushansky, Nathali; Eilam, Raya; Rimmerman, Neta; Levy, Rivka; Ben‐Nun, Avraham; Juknat, Ana et al.. (2011). «Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice» British Journal of Pharmacology 163 (7): 1507–1519. doi: . ISSN 1476-5381. PMID 21449980. PMC PMC3165959. (Noiz kontsultatua: 2020-09-06).
- ↑ Zuardi, A. W.; Crippa, J. a. S.; Hallak, J. E. C.; Moreira, F. A.; Guimarães, F. S.. (2006-04). «Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug» Brazilian Journal of Medical and Biological Research 39 (4): 421–429. doi: . ISSN 0100-879X. (Noiz kontsultatua: 2020-09-06).
- ↑ (Ingelesez) McAllister, Sean D.; Christian, Rigel T.; Horowitz, Maxx P.; Garcia, Amaia; Desprez, Pierre-Yves. (2007-11-01). «Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells» Molecular Cancer Therapeutics 6 (11): 2921–2927. doi: . ISSN 1535-7163. PMID 18025276. (Noiz kontsultatua: 2020-09-06).
- ↑ Pickens, J. T.. (1981-04). «Sedative activity of cannabis in relation to its delta'-trans-tetrahydrocannabinol and cannabidiol content.» British Journal of Pharmacology 72 (4): 649–656. ISSN 0007-1188. PMID 6269680. PMC 2071638. (Noiz kontsultatua: 2020-09-06).
- ↑ (Ingelesez) Nicholson, Anthony N.; Turner, Claire; Stone, Barbara M.; Robson, Philip J.. (2004-06). «Effect of Δ-9-Tetrahydrocannabinol and Cannabidiol on Nocturnal Sleep and Early-Morning Behavior in Young Adults» Journal of Clinical Psychopharmacology 24 (3): 305–313. doi: . ISSN 0271-0749. (Noiz kontsultatua: 2020-09-06).
- ↑ Straus, Stephen E.. (2000-08-15). «Immunoactive cannabinoids: Therapeutic prospects for marijuana constituents» Proceedings of the National Academy of Sciences of the United States of America 97 (17): 9363–9364. ISSN 0027-8424. PMID 10931962. (Noiz kontsultatua: 2020-09-06).